Literature DB >> 8088765

Histopathological classification of childhood rhabdomyosarcomas: relationship with clinical parameters and prognosis.

L C Wijnaendts1, J C van der Linden, A J van Unnik, J F Delemarre, P A Voute, C J Meijer.   

Abstract

To define a useful and prognostically relevant classification system for rhabdomyosarcomas (RMSs), tissue sections of 113 well-documented, protocol-treated cases were retrieved from the files of the Emma Kinderziekenhuis Amsterdam, the Netherlands, and reclassified by a panel of pediatric pathologists. The following subtypes were recognized: embryonal RMS (n = 66), alveolar RMS (including the solid variant) (n = 16), botryoid RMS (n = 11), embryonal sarcoma (n = 6), and spindle cell RMS (n = 5). Nine cases were classified as RMS not otherwise specified (NOS). The above-mentioned histopathological subtypes correlated significantly with survival (P = .005) in patients with nonparameningeal tumors. Indeed, the best prognosis was observed in patients with spindle cell RMS, embryonal sarcoma, and botryoid RMS (10-year survival rates of 80% to 86%). Patients with embryonal RMS had an intermediate prognosis (10-year survival rate of 55%) and patients with alveolar RMS fared poorly (10-year survival rate of 9%). Survival rate was poor in patients with a localized parameningeal tumor, irrespective of histopathological subtype (10-year survival rate of 33%). Furthermore, this study confirmed the known impact on prognosis of localization (P = .008) and tumor node metastasis (TNM) stage (P = .0005). Classification of RMS subtypes proved to be fairly well reproducible (kappa ranging from 0.47 to 0.85 and percentage of concordance ranging from 50% to 85%). The best agreement was noted in botryoid RMS and the worst in embryonal sarcoma. However, improvement of agreement was noted for the latter subtype during the consecutive classification sessions. In summary, this study shows the strong prognostic value of histopathological subtypes and parameningeal tumor localization.

Entities:  

Mesh:

Year:  1994        PMID: 8088765     DOI: 10.1016/0046-8177(94)90009-4

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  8 in total

1.  Massive bone marrow involvement by clear cell variant of rhabdomyosarcoma.

Authors:  Prashant Jani; C Ye Charles
Journal:  Indian J Pediatr       Date:  2009-01-05       Impact factor: 1.967

2.  Tumors of the infratemporal fossa.

Authors:  R Tiwari; J Quak; S Egeler; L Smeele; I V Waal; P V Valk; R Leemans
Journal:  Skull Base Surg       Date:  2000

3.  Microsatellite instability in childhood rhabdomyosarcoma is locus specific and correlates with fractional allelic loss.

Authors:  M Visser; J Bras; C Sijmons; P Devilee; L C Wijnaendts; J C van der Linden; P A Voûte; F Baas
Journal:  Proc Natl Acad Sci U S A       Date:  1996-08-20       Impact factor: 11.205

4.  Primary rhabdomyosarcoma of the breast in a 13-year-old girl: report of a case.

Authors:  Hiroko Nogi; Tadashi Kobayashi; Kazumi Kawase; Isao Tabei; Yasuo Toriumi; Masafumi Suzuki; Makio Kawakami; Toshiaki Morikawa; Ken Uchida
Journal:  Surg Today       Date:  2007-01-01       Impact factor: 2.549

Review 5.  Primary rhabdomyosarcoma of the diaphragm: case report and review of the literature.

Authors:  Marcovalerio Melis; Gerald Rosen; Cristina H Hajdu; H Leon Pachter; Joseph S Raccuia
Journal:  J Gastrointest Surg       Date:  2013-02-09       Impact factor: 3.452

6.  Heparanase activity in alveolar and embryonal rhabdomyosarcoma: implications for tumor invasion.

Authors:  Valentina Masola; Claudio Maran; Evelyne Tassone; Angelica Zin; Angelo Rosolen; Maurizio Onisto
Journal:  BMC Cancer       Date:  2009-08-28       Impact factor: 4.430

Review 7.  Pediatric sclerosing rhabdomyosarcomas: a review.

Authors:  Amandeep Kumar; Manmohan Singh; Mehar C Sharma; Sameer Bakshi; Bhawani S Sharma
Journal:  ISRN Oncol       Date:  2014-03-05

8.  Primary rhabdomyosarcoma of the breast in a 17-year-old girl: Case report.

Authors:  Do Young Kim; Young Mi Seol; Hyojeong Kim; Ahrong Kim; Young Jin Choi
Journal:  Medicine (Baltimore)       Date:  2017-12       Impact factor: 1.817

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.